Study of OPB-201 for recurrent endometrial and platinum-resistant ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called OPB-201 for people with certain gynecologic cancers (endometrial, ovarian, peritoneal, or fallopian tube) that have come back after treatment. The drug is designed to help your immune system recognize and fight cancer cells that carry a specific marker called PRAME.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have endometrial, ovarian, peritoneal, or fallopian tube cancer that has come back after treatment.
- You must have received at least one round of chemotherapy that included a platinum drug (like carboplatin or cisplatin).
- If you have a BRCA gene mutation, you must have already tried a PARP inhibitor.
- You must have a tumor that can be measured on a scan (measurable disease).
- You must be willing to provide a sample of your tumor from a past biopsy or surgery.
- You must be able to do daily activities (performance status 0 or 1), meaning you are up and about rather than bedridden.
- Your organs (like kidneys, liver, etc.) must be working well, which will be checked by blood tests.
- You must have a specific tissue type (HLA-A*02:01 or HLA-A*02:02) and your tumor must be positive for a marker called PRAME.
- You must not be pregnant or breastfeeding, and you must not have active infections, bleeding problems, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Endometrial Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.